ABSTRACT
Human ovarian carcinoma cells (line 2008) grown as subcutaneous solid tumor in the severe combined immunodeflcient mouse can be transfected by directly injecting a plasmid DNA4iposome complex into the tumor (in situ lipofection). The level of reporter gene expression in the tumor cells was significantly elevated if the animal received a single i.p. injection of cisplatin 1 week before the lipofection. Sensitization of the tumor for lipofection peaked 1 week after cisplatin injection and declined thereafter. Cells exposed to low concentration of cisplatin in vitro for four to five doubling times also showed elevated sensitivity for lipofection in vitro. Cisplatin was the only anticancer drug tested that exhibited this activity. These results suggest a sequential combinational gene therapy protocol with cisplatin for the ovarian carcinoma.
Direct gene transfer to the tumor cells by intratumor injection of a plasmid DNA-liposome complex has been reported in animal models (1, 2) and in clinical trials (3) . Expression of a major histocompatibility complex protein (class I) alloantigen in the tumor cells has resulted in the induction of tumorspecific cytotoxic T lymphocyte response in the host, leading to the inhibition of tumor growth and prolongation of the host survival (2) . Direct injection of a DNA-liposome complex into the cutaneous melanoma lesions has also resulted in the alloantigen expression in the tumor cells and partial regression of the tumor in the treated individuals (3, 4) . Thus, efficient transgene expression in the tumor by direct gene transfer can bring therapeutic benefit to the host.
We accidentally found that tumor cells resistant to cisdiamminedichloroplatinum(II) (cisplatin), an anticancer drug, were more transfectable with a cationic liposome-DNA complex than the parent cells (5). Andrews et al. (6) reported that ovarian cancer cells readily developed low-level cisplatin resistance upon cisplatin injection into the tumor-bearing animals. In looking for means to enhance the tumor cell transfection, we have tested whether injection of cisplatin into the host can enhance the sensitivity ofthe tumor to the subsequent injection of a DNA-liposome complex (lipofection). This hypothesis is tested with human ovarian carcinoma cells grown in the severe combined immunodeficient (SCID) mouse.
MATERIALS AND METHODS
Preparation of Plasmid DNA. We have used the bacterial chloramphenicol acetyltransferase (CAT) gene as a reporter to measure transgene expression level (7) . pUCCMVCAT ( (9) . pUCCMVCAT (30 ug (wt/vol) dextrose and then mixed with 30 nmol of DC-choldioleoyl phosphatidylethanolamine liposomes in 15 ,ul of20 mM Hepes (pH 7.8). After 10 min, this complex was injected directly into the tumor in three sites. The animals were sacrificed 2 days later for the examination of CAT gene expression.
Radiometric Assay of CAT Activity. The tumors excised from animals were homogenized in 40 mM Tris-HCl, pH 7.5/10 mM EDTA/150 mM NaCl. After homogenization, cells were lysed by three freeze-thaw cycles, and the lysate was heated at 65°C for 10 min and centrifuged at 16,000 x g for 10 min. The protein concentration of the extracts was measured with a Coomassie blue G250-based assay (BioRad). The protein extract of each tumor (100 ,ug) was then assayed for the CAT activity using [14C]chloramphenicol as a substrate (10) . Lipofection in Vitro. Plasmid pUCCMVCAT in lx TE buffer (0-2.0 ,g) was mixed gently with 10 nmol of DC-choldioleoyl phosphatidylethanolamine liposomes at room temperature in 1 ml of serum-free RPMI 1640 medium, incubated for 10 min, and then added to cells. Cells at 30-40% confluency were washed once with serum-free RPMI 1640 medium. The DNA-liposome complex was added to the cells and incubated at 37°C in 5% C02/95% air for 6 h. Transfection medium was then removed and the washed cells were incubated in the growth medium containing 10% fetal bovine serum for 48 h before the CAT assay as described (11 found that cisplatin at 5 mg/kg resulted in the highest and most reproducible effects. Animals injected with cisplatin at 10 mg/kg died of drug toxicity a few days after injection. At the single dose of 5 mg/kg, no antitumor effect was observed, as the tumor size did not reduce.
We next tested the time course oftumor sensitization. Mice were injected with a single dose of cisplatin (5 mg/kg). Lipofection was done at various times after the drug administration. Fig. 2 shows that there was not a significant enhancement in the efficiency of lipofection at day 3. However, the efficiency reached a peak at 1 week and declined thereafter. This result indicates that the tumor was only transiently sensitized for lipofection. Sensitization by cis- Since there are many different cell types in a solid tumor, it is possible that the cells sensitized by cisplatin were not the tumor cells. We thus directly exposed 2008 cells grown in vitro to low doses of cisplatin for several weeks. The cells did not grow for about a week and then grew slowly. Fig. 3 shows that cells treated continuously with cisplatin for 6 weeks were more transfectable than the untreated cells. Cells treated with 2 ,M cisplatin were about 2-fold more transfectable than those treated with 1 ,M cisplatin. It was estimated that cells had grown for only four or five doubling times during this period. Since tumor cells could be directly sensitized in vitro, it is likely that they are also sensitized in vivo. However, other cell types in the tumor could also be sensitized.
We have tested a number of anticancer drugs to see whether the sensitization activity was unique to cisplatin. Fig. 4 shows that only cisplatin could significantly sensitize the tumor for in situ lipofection. Other anticancer drugs including methotrexate, etoposide, cytosine arabinonucleoside, doxorubicin, and vincristine had no effect. Transplatin, a geometric isomer of cisplatin that has no anticancer activity, also showed no effect. Since carboplatin has similar antitumor activity as cisplatin (12) (13) (14) , it is surprising that it showed no sensitization activity. Perhaps, higher doses of carboplatin are required for the activity.
We have also tested whether cisplatin injection nonspecifically increases the transfectivity of normal cells in the mouse. DNA alone or complexed with liposomes was injected intramuscularly into cisplatin-injected mice. Expression of the CAT gene in the muscles at the injection site was measured. Data in Fig. 5 show that muscles of the cisplatintreated animals did not express higher CAT activity than the muscles from control uninjected animals. Thus, the enhanced sensitivity to lipofection seems to be limited to the tumor cells of the cisplatin-treated animals.
DISCUSSION
Cisplatin induces DNA damage by forming adducts with guanine (15, 16) . Cells undergo a series of complicated genetic and biochemical changes including the induction of DNA repair (17) (18) (19) (20) , glutathione (21, : . , : , w , : . : . 12672 Medical Sciences: Son and Huang (23) (24) (25) (26) , and membrane transport (27) (28) (29) 
